Rana Ramesh, Wang Sheng-Lan, Li Jing, Xia Lu, Song Mei-Yi, Yang Chang-Qing
Division of Gastroenterology and Hepatology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Division of Gastroenterology and Hepatology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China -
Minerva Med. 2017 Dec;108(6):554-567. doi: 10.23736/S0026-4806.17.05136-9. Epub 2017 Jun 9.
Alcoholic hepatitis (AH) is an acute and severe form of alco1holic liver disease associated with high morbidity and mortality of 30-50% worldwide, severity ranging from asymptomatic derangement of liver biochemistries to fulminant liver failure or death. Rapidly progressing jaundice and coagulopathy in prolonged excessive alcohol abusers with or without fever, malnutrition, and tender liver are the clinical hallmarks. The prognostic models (Model for end-stage liver disease, Maddrey's discriminant function [MDF], age, serum bilirubin, INR, creatinine [ABIC], Glasgow Alcoholic Hepatitis Score [GAHS], Lille's Score) not only predict the short term mortality, but also guide the clinicians to choose appropriate specific therapy (corticosteroid or pentoxifylline) and as a stopping rule if there is no significant benefits of it. MDF Score is commonly followed in clinical practice, score of >32 would predict short term mortality of around 20-30% at 1 month and 30-40% within 6 months after presentation. The GAHS on day 1 can predict 28 day overall survival outcome accuracy of 81%, which is comparatively higher than MDF Score. Moreover, ABIC Score categorizes risk of deaths (based on 90 days) into low risks (0%), intermediate risk (30%), and high risk (75%). Corticosteroid and pentoxifylline have significant benefits in decreasing mortality (corticosteroid improves survival on 28 day and 84 day of 78% and 59%) in severe disease state (MDF >32 or Lille's Score >0.45 or GAHS >9). Corticosteroid is the initial treatment of choice with infections screening before initiating; however, pentoxifylline is better preferred in case of AH with severe infections and hepatorenal syndrome. Additionally, combination of corticosteroids and N-acetylcysteine decreases development of hepatorenal syndrome, infections, and short-term mortality. However, the Lille Score after corticosteroid therapy of >0.45 after day 7 indicates poor responders or >0.56 indicates null responders. Therefore, in these cases, either therapy has to be stopped or changed to pentoxifylline. In treatment failure cases, liver transplantation is the ultimate option. However, the facilitating of this service in most transplant centers is a challenge. Beside these specific therapies, alcohol abstinence and recommendation of nutritional supplements with high calorie, protein diet and vitamin E, C, thiamine regardless of other treatment plays a prime role in preventing disease progression and survival benefits even in pre and post-transplant cases.
酒精性肝炎(AH)是酒精性肝病的一种急性重症形式,在全球范围内发病率和死亡率高达30%-50%,严重程度从无症状的肝脏生化指标紊乱到暴发性肝衰竭或死亡不等。长期酗酒者迅速进展的黄疸和凝血功能障碍,伴或不伴有发热、营养不良以及肝脏压痛,是其临床特征。预后模型(终末期肝病模型、马德雷判别函数[MDF]、年龄、血清胆红素、国际标准化比值、肌酐[ABIC]、格拉斯哥酒精性肝炎评分[GAHS]、里尔评分)不仅能预测短期死亡率,还能指导临床医生选择合适的特异性治疗方法(皮质类固醇或己酮可可碱),并作为是否停止治疗的依据,如果治疗没有显著益处的话。MDF评分在临床实践中较为常用,评分>32预测1个月时短期死亡率约为20%-30%,就诊后6个月内为30%-40%。第1天的GAHS能预测28天总体生存结局,准确率为81%,相对高于MDF评分。此外,ABIC评分将死亡风险(基于90天)分为低风险(0%)、中度风险(30%)和高风险(75%)。在重症状态下(MDF>32或里尔评分>0.45或GAHS>9),皮质类固醇和己酮可可碱在降低死亡率方面有显著益处(皮质类固醇可提高28天和84天的生存率,分别为78%和59%)。皮质类固醇是初始治疗的首选,开始治疗前需进行感染筛查;然而,对于伴有严重感染和肝肾综合征的AH患者,己酮可可碱更受青睐。此外,皮质类固醇与N-乙酰半胱氨酸联合使用可减少肝肾综合征、感染的发生以及短期死亡率。然而,皮质类固醇治疗7天后里尔评分>0.45表明反应不佳,>0.56表明无反应。因此,在这些情况下,要么停止治疗,要么改为使用己酮可可碱。在治疗失败的病例中,肝移植是最终选择。然而,在大多数移植中心,提供这项服务是一项挑战。除了这些特异性治疗方法外,戒酒以及推荐高热量、高蛋白饮食和维生素E、C、硫胺素的营养补充剂,无论是否进行其他治疗,在预防疾病进展和生存获益方面都起着重要作用,即使在移植前后的病例中也是如此。